that using a novel skull-implantable grid of nine ultrasound emitters made by French biotech company Carthera can open the blood-brain barrier in a volume of the brain nine times larger than the small single-ultrasound emitter implants originally used. This importantly helps treat a large region of the brain next to the cavity that remains after glioblastoma tumors are removed.
An animation of the SonoCloud-9 implantable ultrasound device. The SonoCloud-9 device uses pulsed ultrasound to transiently disrupt the blood-brain barrier to improve the delivery of chemotherapy to brain tumors. CREDIT: CarThera.after being opened by the ultrasound. It closes in the first 30 to 60 minutes after the communication. and this will help scientists optimize what order to deliver the drugs to allow for better penetration of the brain.
According to Sonobend, the current chemotherapy used for glioblastoma does cross the blood-brain barrier, but is weak. Sonabend also said that previous studies that injected paclitaxel directly into the brains of patients with these tumors had promising signs of efficacy, but the direct injection was associated with toxicity such as brain irritation and meningitis.
A phase 2 clinical trial is already underway. “While we have focused on brain cancer , this opens the door to investigate novel drug-based treatments for millions of patients who suffer from various brain diseases,”